Lermed is developing several approaches to improve diagnosis, prognosis and overall care for patients with neurodegenerative diseases. It leverages two proprietary platforms to generate in-vitro avatars of patients, thus reproducing disease states to conduct clinical trials in a dish, identify responders and devise companion tests for drug development. This groundbreaking approach has the potential to unlock personalised medicine in the field of neurodegeneration and dementia.
Company Details
- Employees
- 2
- Address
- Lausanne, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://lermed.ch
- Keywords
- Biotechnology, Biomarkers, Liquid biopsy, Stem cells, Clinical-trials-in-a-dish, Neurodegeneration.
- HQ
- Lausanne
Lermed Questions
Lermed's website is http://lermed.ch
Lermed's LinkedIn profile is https://ch.linkedin.com/company/lermed-ch
Lermed has
2 employees.
View email and phone details for 2
employees at Lermed.
Lermed's industry is
Biotechnology Research
Lermed's top competitors are
Azurecell,
Lirm - Lemanic Institute For Regenerative Medicine,
Hedera Dx,
Sciencescape,
Leman Biotech,
Fluosphera,
Katapult,
Limula,
Nd Biosciences,
Biopôle Lausanne.
Lermed's categories are Biotechnology Research
